Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
Nutting C, Finneran L, Roe J, Sydenham MA, Beasley M, Bhide S, Boon C, Cook A, De Winton E, Emson M, Foran B, Frogley R, Petkar I, Pettit L, Rooney K, Roques T, Srinivasan D, Tyler J, Hall E; DARS Trialist Group. Nutting C, et al. Among authors: emson m. Lancet Oncol. 2023 Aug;24(8):868-880. doi: 10.1016/S1470-2045(23)00265-6. Epub 2023 Jul 6. Lancet Oncol. 2023. PMID: 37423227 Free article. Clinical Trial.
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A'Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group. Nutting CM, et al. Among authors: emson m. Lancet Oncol. 2011 Feb;12(2):127-36. doi: 10.1016/S1470-2045(10)70290-4. Epub 2011 Jan 12. Lancet Oncol. 2011. PMID: 21236730 Free PMC article. Clinical Trial.
Current attitudes of head and neck oncologists in the United Kingdom to induction chemotherapy for locally advanced head and neck cancer: a survey of centres participating in a national randomised controlled trial.
Gujral DM, Piercy D, Morden JP, Emson M, Hall E, Miah AB, Bhide SA, Newbold KL, Harrington KJ, Nutting CM. Gujral DM, et al. Among authors: emson m. Oral Oncol. 2014 Feb;50(2):141-6. doi: 10.1016/j.oraloncology.2013.10.012. Epub 2013 Nov 18. Oral Oncol. 2014. PMID: 24263110
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
Petkar I, Rooney K, Roe JW, Patterson JM, Bernstein D, Tyler JM, Emson MA, Morden JP, Mertens K, Miles E, Beasley M, Roques T, Bhide SA, Newbold KL, Harrington KJ, Hall E, Nutting CM. Petkar I, et al. Among authors: emson ma. BMC Cancer. 2016 Oct 6;16(1):770. doi: 10.1186/s12885-016-2813-0. BMC Cancer. 2016. PMID: 27716125 Free PMC article.
Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004).
Nutting CM, Morden JP, Beasley M, Bhide S, Cook A, De Winton E, Emson M, Evans M, Fresco L, Gollins S, Gujral D, Harrington K, Joseph M, Lemon C, Luxon L, van den Blink Q, Mendes R, Miah A, Newbold K, Prestwich R, Robinson M, Sanghera P, Simpson J, Sivaramalingam M, Srihari NN, Sydenham M, Wells E, Witts S, Hall E; COSTAR Investigators. Nutting CM, et al. Among authors: emson m. Eur J Cancer. 2018 Nov;103:249-258. doi: 10.1016/j.ejca.2018.08.006. Epub 2018 Oct 1. Eur J Cancer. 2018. PMID: 30286418 Free PMC article. Clinical Trial.
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.
Nutting CM, Griffin CL, Sanghera P, Foran B, Beasley M, Bernstein D, Cosgrove V, Fisher S, West CM, Sibtain A, Palaniappan N, Urbano TG, Sen M, Soe W, Rizwanullah M, Wood K, Ramkumar S, Junor E, Cook A, Roques T, Scrase C, Bhide SA, Gujral D, Harrington KJ, Mehanna H, Miah A, Emson M, Gardiner D, Morden JP, Hall E; ART DECO Trial Management Group. Nutting CM, et al. Among authors: emson m. Eur J Cancer. 2021 Aug;153:242-256. doi: 10.1016/j.ejca.2021.05.021. Epub 2021 Jul 10. Eur J Cancer. 2021. PMID: 34256319 Clinical Trial.
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
Coles CE, Haviland JS, Kirby AM, Griffin CL, Sydenham MA, Titley JC, Bhattacharya I, Brunt AM, Chan HYC, Donovan EM, Eaton DJ, Emson M, Hopwood P, Jefford ML, Lightowlers SV, Sawyer EJ, Syndikus I, Tsang YM, Twyman NI, Yarnold JR, Bliss JM; IMPORT Trial Management Group. Coles CE, et al. Among authors: emson m. Lancet. 2023 Jun 24;401(10394):2124-2137. doi: 10.1016/S0140-6736(23)00619-0. Epub 2023 Jun 8. Lancet. 2023. PMID: 37302395 Free article. Clinical Trial.
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, Bhattacharya IS, Brunt AM, Ciurlionis L, Chan C, Donovan EM, Emson MA, Harnett AN, Haviland JS, Hopwood P, Jefford ML, Kaggwa R, Sawyer EJ, Syndikus I, Tsang YM, Wheatley DA, Wilcox M, Yarnold JR, Bliss JM; IMPORT Trialists. Coles CE, et al. Among authors: emson ma. Lancet. 2017 Sep 9;390(10099):1048-1060. doi: 10.1016/S0140-6736(17)31145-5. Epub 2017 Aug 2. Lancet. 2017. PMID: 28779963 Free PMC article. Clinical Trial.
26 results